What level of evidence would you require to add intismeran to adjuvant pembrolizumab in resected stage IIB–IV melanoma if it is approved?

I think it is valuable for patients with stage IIIC and IIID melanoma and warrants integration into their care. For patients with stage IIB, IIIA, and IIIB melanoma, I would like to see the full paper with an individual breakdown. In my opinion, the lack of OS benefit remains an existential question...

I would at least wait for the NEJM article before changing practice. Also, cost will be an issue. OS remains the gold standard for optimal therapy.